Matches in SemOpenAlex for { <https://semopenalex.org/work/W2418458020> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2418458020 endingPage "58" @default.
- W2418458020 startingPage "56" @default.
- W2418458020 abstract "Objective To study the impact of two human glioma tissue resistance genes MGMT and ERCC2 on the temozolomide-based treatment of malignant gliomas and detect the relationship of their expressions. Methods A total of 58 malignant glioma patients aged 19 -68 years old receiving a chemotherapy of temozolomide were followed up and classified as non-sensitive group (n = 30) and sensitive group (n = 28). Immunohistochemistry was employed to detect the expression rates of MGMT and ERCC2.And the correlation between the expressions of two genes was analyzed by immunohistochemistry and RT-PCR (reverse transcription-polymerase chain reaction). Results The expression rates of MGMT and ERCC2were 10. 71% and 3.57% in the sensitive group and 63.33% and 56. 67% in the non-sensitive group. It had an obvious correlation with the expressions of MEGT and ERCC2 through an analysis of immunohistochemistry and RT-PCR (both P ＜0. 01 ). Conclusion The expressions of MGMT and ERCC2in the sensitive group are markedly lower than those in the non-sensitive group. The expression of two genes may be related to tumor prognosis. Maybe these two genes have an intrinsic link between their expressions.Both participate in the repair of cellular DNA damage and the formation of tumor drug resistance. And the prognosis has obvious relevance.Key words: Glioma; MGMT protein; ERCC2 protein; Temozolomide" @default.
- W2418458020 created "2016-06-24" @default.
- W2418458020 creator A5016554833 @default.
- W2418458020 creator A5028330071 @default.
- W2418458020 creator A5032024216 @default.
- W2418458020 creator A5066629372 @default.
- W2418458020 creator A5070999062 @default.
- W2418458020 creator A5087240893 @default.
- W2418458020 date "2011-01-04" @default.
- W2418458020 modified "2023-09-24" @default.
- W2418458020 title "[Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship]." @default.
- W2418458020 doi "https://doi.org/10.3760/cma.j.issn.0376-2491.2011.01.015" @default.
- W2418458020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21418965" @default.
- W2418458020 hasPublicationYear "2011" @default.
- W2418458020 type Work @default.
- W2418458020 sameAs 2418458020 @default.
- W2418458020 citedByCount "1" @default.
- W2418458020 countsByYear W24184580202021 @default.
- W2418458020 crossrefType "journal-article" @default.
- W2418458020 hasAuthorship W2418458020A5016554833 @default.
- W2418458020 hasAuthorship W2418458020A5028330071 @default.
- W2418458020 hasAuthorship W2418458020A5032024216 @default.
- W2418458020 hasAuthorship W2418458020A5066629372 @default.
- W2418458020 hasAuthorship W2418458020A5070999062 @default.
- W2418458020 hasAuthorship W2418458020A5087240893 @default.
- W2418458020 hasConcept C104317684 @default.
- W2418458020 hasConcept C104451858 @default.
- W2418458020 hasConcept C114851261 @default.
- W2418458020 hasConcept C126322002 @default.
- W2418458020 hasConcept C134935766 @default.
- W2418458020 hasConcept C143998085 @default.
- W2418458020 hasConcept C204232928 @default.
- W2418458020 hasConcept C2777389519 @default.
- W2418458020 hasConcept C2778227246 @default.
- W2418458020 hasConcept C2778883343 @default.
- W2418458020 hasConcept C502942594 @default.
- W2418458020 hasConcept C54355233 @default.
- W2418458020 hasConcept C71924100 @default.
- W2418458020 hasConcept C86803240 @default.
- W2418458020 hasConceptScore W2418458020C104317684 @default.
- W2418458020 hasConceptScore W2418458020C104451858 @default.
- W2418458020 hasConceptScore W2418458020C114851261 @default.
- W2418458020 hasConceptScore W2418458020C126322002 @default.
- W2418458020 hasConceptScore W2418458020C134935766 @default.
- W2418458020 hasConceptScore W2418458020C143998085 @default.
- W2418458020 hasConceptScore W2418458020C204232928 @default.
- W2418458020 hasConceptScore W2418458020C2777389519 @default.
- W2418458020 hasConceptScore W2418458020C2778227246 @default.
- W2418458020 hasConceptScore W2418458020C2778883343 @default.
- W2418458020 hasConceptScore W2418458020C502942594 @default.
- W2418458020 hasConceptScore W2418458020C54355233 @default.
- W2418458020 hasConceptScore W2418458020C71924100 @default.
- W2418458020 hasConceptScore W2418458020C86803240 @default.
- W2418458020 hasIssue "1" @default.
- W2418458020 hasLocation W24184580201 @default.
- W2418458020 hasLocation W24184580202 @default.
- W2418458020 hasOpenAccess W2418458020 @default.
- W2418458020 hasPrimaryLocation W24184580201 @default.
- W2418458020 hasRelatedWork W1607924860 @default.
- W2418458020 hasRelatedWork W1964422747 @default.
- W2418458020 hasRelatedWork W1969344794 @default.
- W2418458020 hasRelatedWork W1987028324 @default.
- W2418458020 hasRelatedWork W1988255080 @default.
- W2418458020 hasRelatedWork W1991238803 @default.
- W2418458020 hasRelatedWork W2054548389 @default.
- W2418458020 hasRelatedWork W2076665358 @default.
- W2418458020 hasRelatedWork W2085546635 @default.
- W2418458020 hasRelatedWork W2098548617 @default.
- W2418458020 hasRelatedWork W2137868544 @default.
- W2418458020 hasRelatedWork W2364056538 @default.
- W2418458020 hasRelatedWork W2364979943 @default.
- W2418458020 hasRelatedWork W2369709166 @default.
- W2418458020 hasRelatedWork W2388308265 @default.
- W2418458020 hasRelatedWork W2768319756 @default.
- W2418458020 hasRelatedWork W2805756200 @default.
- W2418458020 hasRelatedWork W2955590078 @default.
- W2418458020 hasRelatedWork W3028648404 @default.
- W2418458020 hasRelatedWork W3030591575 @default.
- W2418458020 hasVolume "91" @default.
- W2418458020 isParatext "false" @default.
- W2418458020 isRetracted "false" @default.
- W2418458020 magId "2418458020" @default.
- W2418458020 workType "article" @default.